Work

A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies

Year: 2007

Type: article

Study design: Clinical Trial

Source: Molecular Cancer Therapeutics

Authors: Ravi Salgia, David S. Hong, Steven Sherman, Chann Ng, John Frye, Linda Janish, Mark J. Ratain, Razelle Kurzrock

Institutions: Exelixis (United States), University of Chicago Medical Center

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2285511451

FWCI: 0.659

Cites:

Cited by: 8

Related to: 10